An evolved ribosome-inactivating protein targets and kills human melanoma cells <it>in vitro </it>and <it>in vivo</it>
<p>Abstract</p> <p>Background</p> <p>Few treatment options exist for patients with metastatic melanoma, resulting in poor prognosis. One standard treatment, dacarbazine (DTIC), shows low response rates ranging from 15 to 25 percent with an 8-month median survival time....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-02-01
|
| Series: | Molecular Cancer |
| Online Access: | http://www.molecular-cancer.com/content/9/1/28 |